You are here: Industry Insights > CDMO

News List

TriRx Completes Acquisition of Elanco Animal Health Facility contractpharma
August 09, 2021
Site in Shawnee, KS to become a global center of excellence serving the pharmaceutical contract development and manufacturing market.
GRAM Expands Footprint with New Finishing Center contractpharma
August 09, 2021
New 110,000 sq.-ft. finishing center is the injectable CDMO's fourth GMP manufacturing facility.
Global API CDMO market to value almost $140bn by 2028 europeanpharmaceuticalreview
August 06, 2021
Market research suggests the Asia Pacific region could soon overtake Europe and North America in the active pharmaceutical ingredient (API) contract development and manufacturing organisation (CDMO) market.
Tech transfer: a many-layered artform that demands precision and communication cphi-online
August 04, 2021
Tech transfer is a crucial phase that converts clinical promise into commercial gain but pressure on sponsors to reduce time to market in the age of COVID-19 means CDMOs have to be on top of their game to deliver.
Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028 contractpharma
August 02, 2021
Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.
Diversification and addition of capabilities key to CDMO success as end markets grow: CPhI North America panel prnewswire
July 30, 2021
CDMOs need to diversify and expand their capabilities to take full advantage of strong growth in prominent end markets such as small molecule, monoclonal antibodies and cell and gene therapy, according to an industry expert on a panel at the CPhI.
Pandemic and transformative technologies fuel growth in pharma outsourcing sector: CPhI North America panel cphi-online
July 28, 2021
Transformative technologies and the opportunities afforded by the COVID-19 pandemic have spurred investment in the life sciences outsourcing sector, according to a panel of industry experts speaking at CPhI North America on Monday.
Vetter’s New Clinical Mfg. Site Now Fully Integrated contractpharma
July 22, 2021
Vetter, a global CDMO, has further invested in additional capacity to meet the growing global demand for clinical manufacturing for injectable drug products.
Samsung Biologics and Kineta strike cancer immunotherapy development and manufacturing deal cphi-online
July 22, 2021
Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours
Vetter’s New Clinical Manufacturing Site Now Fully Integrated b3cnewswire
July 22, 2021
A growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners that provide strategic support and comprehensive resources for their development process of new, promising injectable drug products.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 29 30 Next page